Branford, D. A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. J Intellect Disabil Res
1994; 38: 577–86.
Holden, B, Gitlesen, JP. Psychotropic medication in adults with mental retardation: prevalence, and prescription practices. Res Dev Disabil
2004; 25: 509–21
Kiernan, C, Reeves, D, Alborz, A. The use of anti-psychotic drugs with adults with learning disabilities and challenging behaviour. J Intellect Disabil Res
1995; 39: 263–74.
Brylewski, J, Duggan, L. Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database of Systematic Reviews
2004; 2: CD000377.
Singh, AN, Matson, JL, Cooper, CL, Dixon, D, Sturmey, P. The use of risperidone among individuals with mental retardation: clinically supported or not?
Res Dev Disabil
2005; 26: 203–18.
Tyrer, P, Oliver-Africano, PC, Ahmed, Z, Bouras, N, Cooray, S, Deb, S, et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet
2008; 371: 57–63.
Henderson, DC, Doraiswamy, PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry
2008; 69 (suppl 1): 32–44.
McKee, JR, Bodfish, JW, Mahorney, SL, Heeth, WL, Ball, MP. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. J Clin Psychiatry
2005; 66: 1161–8.
Hellings, JA, Zarcone, JR, Valdovinos, MG, Reese, RM, Gaughan, E, Schroeder, SR. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J Child Adolesc Psychopharmacol
2005; 15: 885–92.
Turgay, A, Binder, C, Snyder, R, Fisman, S. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics
2002; 110: e34.
Handen, BL, Hardan, AY. Open-label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders. J Am Acad Child Adolesc Psychiatry
2006; 45: 928–35.
Devapriam, J, Anand, A, Raju, LB, Bhaumik, S. Monitoring for metabolic syndrome in adults with intellectual disability on atypical antipsychotic drugs. Br J Dev Disabilities
2009; 55 (Pt 1): 3–13.
Tan, GD, Neville, MJ, Liverani, E, Humphreys, SM, Currie, JM, Dennis, L, et al. The in vivo effects of the Pro12Ala PPARgamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia
2006; 49: 158–68.
Department for Constitutional Affairs. Mental Capacity Act 2005 Code of Practice. TSO (The Stationery Office), 2007.
Friedewald, WT, Levy, RI, Fredrickson, DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chemistry
1972; 18: 499–502.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). APA, 1994.
Woods, SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry
2003; 64: 663–7.
Taylor, D, Paton, C, Kervin, R. The Maudsley Prescribing Guidelines (9th edn). Informa Healthcare, 2007.
British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary
. BMJ Group and Pharmaceutical Press, 2010.
Uchida, H, Suzuki, DC, Mamo, BH, Mulstant, BH, Tanabe, A, Inagaki, A, et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia sectrum disorders: a survey of 1,418 patients in Japan. Am Geriatr Psychiatry
2008; 16: 584–93.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Ahmed, Z, Fraser, W, Kerr, MP, Kiernan, C, Emerson, E, Robertson, J, et al. Reducing antipsychotic medication in people with a learning disability. Br J Psychiatry
2000; 176: 42–6.
Gagiano, C, Read, S, Thorpe, L, Eerdekens, M, Van Hove, I. Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders. Psychopharmacol
2005; 179: 629–36.
Deb, S, Sohanpal, SK, Soni, R, Lenotre, L, Unwin, G. The effectiveness of antipsychotic medication in the management of behaviour problems in adults with intellectual disabilities. J Intellect Disabil Res
2007; 51: 766–77.
McEvoy, JP, Meyer, JM, Goff, DC, Nasrallah, HA, Davis, SM, Sullivan, L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res
2005; 80: 19–32.
Robertson, J, Emerson, E, Gregory, N, Hatton, C, Turner, S, Kessissoglous, , et al. Lifestyle related risk factors for poor health in residential settings for people with intellectual disabilities. Res Dev Disabil
2000; 21: 469–86.
Emerson, E. Underweight, obesity and exercise among adults with intellectual disabilities in supported accommodation in Northern England. J Intellect Disabil Res
2005; 49: 134–43.
Kuruvilla, A, Peedicayil, J, Srikrishna, G, Kuruvilla, K, Kanagasabapathy, AS. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol
1992; 19: 603–6.
Bushe, C, Yeomans, D, Floyd, T, Smith, SM. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol
2008; 22: 56–62.
O'Keane, V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol
2008; 22: 70–5.
Klibanski, A, Neer, RM, Beitins, IZ, Ridgway, EC, Zervas, NT, McArthur, JW. Decreased bone density in hyperprolactinemic women. N Engl J Med
1980; 303: 1511–4.
Greenspan, SL, Neer, RM, Ridgway, EC, Klibanski, A. Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med
1986; 104: 777–82.
Hawli, Y, Nasrallah, M, El-Hajj Fuleihan, G. Endocrine and musculoskeletal abnormalities in patients with Down syndrome. Nature Rev
2009; 5: 327–34.
Schrager, S. Epidemiology of osteoporosis in women with cognitive impairment. Ment Retard
2006; 44: 203–11.
Vanlint, S, Nugent, M. Vitamin D and fractures in people with intellectual disability. J Intellect Disabil Res
2006; 50: 761–7.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care
2004; 27: 596–601.